Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
Vera Therapeutics said TRUTAKNA stabilized eGFR and prevented kidney-disease progression through two years in the final ORIGIN 3 analysis for IgA nephropathy. The result strengthens the drug’s long-term efficacy case, but the announcement does not disclose the numerical efficacy results or the next regulatory milestone.
WRONG IFThe setup fails if the full ORIGIN 3 results show a small or statistically weak treatment effect, unfavorable safety, or no clear regulatory path despite the announcement’s favorable wording.





